リポソームドラッグデリバリーデバイスの世界市場レポート 2025年

リポソームドラッグデリバリーデバイス市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.4％で86億1,000万米ドルに成長します。予測期間の成長は、標的療法の拡大、臨床検証と臨床試験、個別化医療の重視、併用療法の開発、規制状況の変化に起因すると考えられます。予測期間における主な動向としては、生体適合性リポソーム材料、送達システムの革新、がん領域への応用、併用療法、リポソーム製剤のカスタマイズなどが挙げられます。

世界のがん患者数の増加が、予測期間中のリポソームドラッグデリバリーデバイス市場の成長を牽引すると予想されます。リポソームドラッグデリバリーシステムは、放射線療法、化学療法、外科的切除を含むがん治療の標的療法として採用されています。例えば、英国を拠点とするがん慈善団体Macmillan Cancer Supportが2022年6月に発表したデータによると、がん患者数は2022年に300万人に達し、英国では2025年までに約350万人、2030年までに400万人に増加すると予測されています。このように、世界のがん罹患率の増加は、今後数年間でリポソームドラッグデリバリーデバイスの需要を高めると予測されています。

ヘルスケア支出の増加は、今後リポソームドラッグデリバリーデバイス市場の成長を加速させると予想されます。このようなヘルスケア支出の増加は、慢性疾患の蔓延、医療技術の進歩、薬価の上昇、消費者の期待、保険料など、相互に関連するいくつかの要因に起因しています。ヘルスケア支出には、リポソームドラッグデリバリーデバイスに関連する費用を含む、幅広い医療・ヘルスケア関連費用が含まれます。これらの支出は、リポソーム薬物送達システムのような医療技術や機器の研究開発、製造、流通、利用など、ヘルスケアの様々な側面をカバーしています。例えば、米国のコンサルティング会社であるピーターG財団が2022年7月に発表した報告書では、公的・私的ヘルスケア支出は、2022年の4兆4,000億米ドル（1人当たり1万3,413米ドル）から、2031年には7兆2,000億米ドル（1人当たり2万425米ドル）に増加すると予測しています。GDPに対する国民医療費（NHE）は、医療費が経済成長を上回るスピードでエスカレートしているため、2022年の17.4％から2031年には約20％まで増加すると予想されています。したがって、ヘルスケア支出の増加がリポソームドラッグデリバリーデバイス市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リポソームドラッグデリバリーデバイス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のリポソームドラッグデリバリーデバイス市場：成長率分析
• 世界のリポソームドラッグデリバリーデバイス市場の実績：規模と成長, 2019-2024
• 世界のリポソームドラッグデリバリーデバイス市場の予測：規模と成長, 2024-2029, 2034F
• 世界リポソームドラッグデリバリーデバイス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリポソームドラッグデリバリーデバイス市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポソームドキソルビシン
• リポソームパクリタキセル
• リポソームアムホテリシンB
• 世界のリポソームドラッグデリバリーデバイス市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 真菌性疾患
• がん治療
• 疼痛管理
• ウイルスワクチン
• 光線力学療法
• 世界のリポソームドラッグデリバリーデバイス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• 外来手術センター/クリニック
• その他のエンドユーザー
• 世界のリポソームドラッグデリバリーデバイス市場リポソームドキソルビシンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のリポソームドキソルビシン
• PEG化リポソームドキソルビシン
• 世界のリポソームドラッグデリバリーデバイス市場リポソームパクリタキセルの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のリポソームパクリタキセル
• PEG化リポソームパクリタキセル
• 世界のリポソームドラッグデリバリーデバイス市場、リポソームアムホテリシンBのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のリポソームアムホテリシンB
• PEG化リポソームアムホテリシンB
• 世界のリポソームドラッグデリバリーデバイス市場、その他のタイプのサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポソームイリノテカン
• リポソームビンクリスチン
• リポソームシタラビン

第7章 地域別・国別分析

• 世界のリポソームドラッグデリバリーデバイス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリポソームドラッグデリバリーデバイス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リポソームドラッグデリバリーデバイス市場：競合情勢
• リポソームドラッグデリバリーデバイス市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• CSPC Pharmaceutical Group Limited
• Ipsen SA
• Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd.
• Nanomerics Ltd.
• Luye Pharma Group Ltd.
• Leadiant Biosciences Inc.
• Pacira Biosciences Inc.
• Nippon Kayaku Co. Ltd.
• Celsion Corporation
• Acrotech Biopharma Inc.
• Aphios Pharma LLC
• CytImmune Sciences Inc.
• NanoSphere Health Sciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リポソームドラッグデリバリーデバイス市場2029：新たな機会を提供する国
• リポソームドラッグデリバリーデバイス市場2029：新たな機会を提供するセグメント
• リポソームドラッグデリバリーデバイス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Liposomal drug delivery devices are microscopic colloidal spheres utilized to transport drug molecules to specific action sites.

Primary types encompass liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin, a chemotherapy drug under the anthracycline category, encapsulated within a liposome, inhibits cancer cell growth by blocking the enzyme topoisomerase. These devices find applications in treating fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy, utilized in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and similar medical settings.

The liposomal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal drug delivery devices market size has grown rapidly in recent years. It will grow from $4.89 billion in 2024 to $5.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to drug delivery advancements, biomedical research, clinical validation, therapeutic applications, and biocompatibility enhancements.

The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to targeted therapies expansion, clinical validation and trials, personalized medicine emphasis, combination therapies development, regulatory landscape changes. Major trends in the forecast period include biocompatible liposomal materials, innovations in delivery systems, application in oncology, combination therapies, customized liposome formulations.

The increasing number of cancer cases worldwide is expected to drive the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are employed as targeted therapies for cancer treatments, including radiation therapy, chemotherapy, and surgical resection. For instance, data published by Macmillan Cancer Support, a UK-based cancer charity, in June 2022, indicated that the number of individuals living with cancer reached 3 million in 2022 and is projected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Thus, the global increase in cancer incidence is anticipated to enhance the demand for liposomal drug delivery devices in the coming years.

Rising healthcare expenditure is expected to accelerate the growth of the liposomal drug delivery devices market in the future. This increase in healthcare spending can be attributed to several interconnected factors, including the growing prevalence of chronic diseases, advancements in medical technology, rising drug prices, consumer expectations, and insurance costs. Healthcare expenditure includes a wide range of medical and healthcare-related costs, encompassing expenses associated with liposomal drug delivery devices. These expenditures cover various facets of healthcare, including the research, development, manufacturing, distribution, and utilization of medical technologies and devices like liposomal drug delivery systems. For example, a report from the Peter G Foundation, a US-based consulting firm, in July 2022, projected that both public and private healthcare spending would rise from $4.4 trillion, or $13,413 per person, in 2022 to $7.2 trillion, or $20,425 per person, by 2031. In relation to GDP, National Healthcare Expenditure (NHE) is expected to increase from 17.4% in 2022 to approximately 20% by 2031, as healthcare costs escalate faster than economic growth. Therefore, the rising healthcare expenditure is driving the growth of the liposomal drug delivery devices market.

Numerous large companies are implementing various strategic initiatives, including new product development, which is expected to become a significant trend in the liposomal drug delivery devices market. These companies are collaborating to create liposomal drug delivery systems to enhance their product portfolios and expand their global operations. For example, in May 2024, Insmed, Inc., a US-based biotech firm, announced data from the ARISE study regarding ARIKAYCE (amikacin liposome inhalation suspension). Patients treated with ARIKAYCE demonstrated better outcomes than those receiving the comparator arm (a macrolide-based multi-drug regimen), as measured by the QOL-B instrument, with 43.8% of patients showing an improvement in their QOL-B respiratory score.

Key players in the liposomal drug delivery market are launching innovative products like liposomal nanostructures to gain a competitive advantage. Researchers have been focused on developing these nanostructures to enhance patient compliance by allowing for less frequent dosing while maintaining effectiveness. For instance, in February 2022, the National Center for Biotechnology Information reported that several commercial nano-liposomal products, such as Onivyde, Vyxeos, and Marqibo, have been approved and are currently utilized. These medications are specifically used in cancer treatment for certain types of leukemia or solid tumors, playing a vital role in oncology by providing therapeutic options for cancers that may resist conventional chemotherapy or necessitate liposomal drug delivery.

Leading companies in the liposomal drug delivery market are introducing groundbreaking products such as hydrochloride liposome injection to establish a competitive edge. Researchers are focused on creating liposomal nanostructures that improve patient compliance by enabling less frequent dosing while ensuring efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection in two formulations: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). As of June 2024, this injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market. This positions Lupin strategically within the oncology segment, expanding its portfolio to include this significant cancer treatment option. Lupin's commitment to enhancing patient health outcomes is reflected in this launch, as it aims to provide effective treatment alternatives in a competitive pharmaceutical landscape.

Major companies operating in the liposomal drug delivery devices market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., CSPC Pharmaceutical Group Limited, Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company, T&T Scientific Corporation

North America was the largest region in the liposomal drug delivery devices market in 2024. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market share. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liposomal Drug Delivery Devices Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liposomal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liposomal drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liposomal drug delivery devices market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Liposomal Doxorubicin; Liposomal Paclitaxel; Liposomal Amphotericin B; Other Types
• 2) By Application: Fungal Diseases; Cancer Therapy; Pain Management; Viral Vaccines; Photodynamic Therapy
• 3) By End User: Hospitals; Diagnostic Centers; Ambulatory Surgery Centers/Clinics; Other End Users
• Subsegments:
• 1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin; PEGylated Liposomal Doxorubicin
• 2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel; PEGylated Liposomal Paclitaxel
• 3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B; PEGylated Liposomal Amphotericin B
• 4) By Other Types: Liposomal Irinotecan; Liposomal Vincristine; Liposomal Cytarabine
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Novartis AG; Gilead Sciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liposomal Drug Delivery Devices Market Characteristics

3. Liposomal Drug Delivery Devices Market Trends And Strategies

4. Liposomal Drug Delivery Devices Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liposomal Drug Delivery Devices Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liposomal Drug Delivery Devices PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liposomal Drug Delivery Devices Market Growth Rate Analysis
• 5.4. Global Liposomal Drug Delivery Devices Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liposomal Drug Delivery Devices Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liposomal Drug Delivery Devices Total Addressable Market (TAM)

6. Liposomal Drug Delivery Devices Market Segmentation

• 6.1. Global Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• 6.2. Global Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fungal Diseases
• Cancer Therapy
• Pain Management
• Viral Vaccines
• Photodynamic Therapy
• 6.3. Global Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Ambulatory Surgery Centers/Clinics
• Other End Users
• 6.4. Global Liposomal Drug Delivery Devices Market, Sub-Segmentation Of Liposomal Doxorubicin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Liposomal Doxorubicin
• PEGylated Liposomal Doxorubicin
• 6.5. Global Liposomal Drug Delivery Devices Market, Sub-Segmentation Of Liposomal Paclitaxel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Liposomal Paclitaxel
• PEGylated Liposomal Paclitaxel
• 6.6. Global Liposomal Drug Delivery Devices Market, Sub-Segmentation Of Liposomal Amphotericin B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Liposomal Amphotericin B
• PEGylated Liposomal Amphotericin B
• 6.7. Global Liposomal Drug Delivery Devices Market, Sub-Segmentation Of Other Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposomal Irinotecan
• Liposomal Vincristine
• Liposomal Cytarabine

7. Liposomal Drug Delivery Devices Market Regional And Country Analysis

• 7.1. Global Liposomal Drug Delivery Devices Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liposomal Drug Delivery Devices Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liposomal Drug Delivery Devices Market

• 8.1. Asia-Pacific Liposomal Drug Delivery Devices Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liposomal Drug Delivery Devices Market

• 9.1. China Liposomal Drug Delivery Devices Market Overview
• 9.2. China Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liposomal Drug Delivery Devices Market

• 10.1. India Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liposomal Drug Delivery Devices Market

• 11.1. Japan Liposomal Drug Delivery Devices Market Overview
• 11.2. Japan Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liposomal Drug Delivery Devices Market

• 12.1. Australia Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liposomal Drug Delivery Devices Market

• 13.1. Indonesia Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liposomal Drug Delivery Devices Market

• 14.1. South Korea Liposomal Drug Delivery Devices Market Overview
• 14.2. South Korea Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liposomal Drug Delivery Devices Market

• 15.1. Western Europe Liposomal Drug Delivery Devices Market Overview
• 15.2. Western Europe Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liposomal Drug Delivery Devices Market

• 16.1. UK Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liposomal Drug Delivery Devices Market

• 17.1. Germany Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liposomal Drug Delivery Devices Market

• 18.1. France Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liposomal Drug Delivery Devices Market

• 19.1. Italy Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liposomal Drug Delivery Devices Market

• 20.1. Spain Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liposomal Drug Delivery Devices Market

• 21.1. Eastern Europe Liposomal Drug Delivery Devices Market Overview
• 21.2. Eastern Europe Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liposomal Drug Delivery Devices Market

• 22.1. Russia Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liposomal Drug Delivery Devices Market

• 23.1. North America Liposomal Drug Delivery Devices Market Overview
• 23.2. North America Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liposomal Drug Delivery Devices Market

• 24.1. USA Liposomal Drug Delivery Devices Market Overview
• 24.2. USA Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liposomal Drug Delivery Devices Market

• 25.1. Canada Liposomal Drug Delivery Devices Market Overview
• 25.2. Canada Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liposomal Drug Delivery Devices Market

• 26.1. South America Liposomal Drug Delivery Devices Market Overview
• 26.2. South America Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liposomal Drug Delivery Devices Market

• 27.1. Brazil Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liposomal Drug Delivery Devices Market

• 28.1. Middle East Liposomal Drug Delivery Devices Market Overview
• 28.2. Middle East Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liposomal Drug Delivery Devices Market

• 29.1. Africa Liposomal Drug Delivery Devices Market Overview
• 29.2. Africa Liposomal Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liposomal Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liposomal Drug Delivery Devices Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liposomal Drug Delivery Devices Market Competitive Landscape And Company Profiles

• 30.1. Liposomal Drug Delivery Devices Market Competitive Landscape
• 30.2. Liposomal Drug Delivery Devices Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Liposomal Drug Delivery Devices Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. CSPC Pharmaceutical Group Limited
• 31.4. Ipsen SA
• 31.5. Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd.
• 31.6. Nanomerics Ltd.
• 31.7. Luye Pharma Group Ltd.
• 31.8. Leadiant Biosciences Inc.
• 31.9. Pacira Biosciences Inc.
• 31.10. Nippon Kayaku Co. Ltd.
• 31.11. Celsion Corporation
• 31.12. Acrotech Biopharma Inc.
• 31.13. Aphios Pharma LLC
• 31.14. CytImmune Sciences Inc.
• 31.15. NanoSphere Health Sciences Inc.

32. Global Liposomal Drug Delivery Devices Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liposomal Drug Delivery Devices Market

34. Recent Developments In The Liposomal Drug Delivery Devices Market

35. Liposomal Drug Delivery Devices Market High Potential Countries, Segments and Strategies

• 35.1 Liposomal Drug Delivery Devices Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liposomal Drug Delivery Devices Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liposomal Drug Delivery Devices Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer